Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial

被引：0

作者：

Wu, Lingying ^{[1
]}

Li, Ning ^{[1
]}

Wang, Jing ^{[2
]}

Li, Qingshui ^{[3
]}

Wang, Danbo ^{[4
]}

Tang, Junying ^{[5
]}

Zhang, Cuiying ^{[6
]}

Zhang, Guonan ^{[7
]}

Hao, Min ^{[8
]}

Yao, Desheng ^{[9
]}

Duan, Wei ^{[10
]}

Gao, Qinglei ^{[11
]}

Wang, Li ^{[12
]}

Zhang, Youzhong ^{[13
]}

An, Ruifang ^{[14
]}

Yin, Rutie ^{[15
]}

Zhou, Qi ^{[16
]}

Yang, Hongying ^{[17
]}

Zhu, Jianqing ^{[18
]}

Jiang, Kui ^{[19
]}

Wu, Qiang ^{[20
]}

Zhao, Weidong ^{[21
]}

Huang, Yi ^{[22
]}

Xia, Bairong ^{[23
]}

Yang, Xinfeng ^{[24
]}

Li, Bo ^{[24
]}

机构：

[1] PUMC, Nat Canc Ctr, Canc Hosp, Chinese Acad Med Sci, Beijing, Peoples R China

[2] Hunan Canc Hosp, Changsha, Peoples R China

[3] Shandong First Med Univ, Affiliated Canc Hosp, Shandong, Peoples R China

[4] China Med Univ, Canc Hosp, Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

[5] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China

[6] Inner Mongolia Peoples Hosp, Hohhot, Peoples R China

[7] Sichuan Canc Hosp, Chengdu, Peoples R China

[8] Shanxi Med Univ, Hosp 2, Taiyuan, Peoples R China

[9] Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China

[10] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing, Peoples R China

[11] HUST, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China

[12] Henan Canc Hosp, Zhengzhou, Peoples R China

[13] Shandong Univ, Qilu Hosp, Jinan, Peoples R China

[14] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China

[15] Sichuan Univ, West China Hosp 2, Chengdu, Peoples R China

[16] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China

[17] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China

[18] Zhejiang Canc Hosp, Hangzhou, Peoples R China

[19] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[20] Jiangsu Canc Hosp, Nanjing, Peoples R China

[21] Anhui Prov Hosp, Hefei, Peoples R China

[22] Hubei Canc Hosp, Wuhan, Peoples R China

[23] Anhui Prov Canc Ctr, Hefei, Peoples R China

[24] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

111

引用

页码：S74 / S75

页数：2

共 50 条

[1] Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial
Li, Ning
Zhang, Youzhong
Wang, Jing
Zhu, Jianqing
Wang, Li
Wu, Xiaohua
Yao, Desheng
Wu, Qiang
Liu, Jihong
Tang, Junying
Yin, Rutie
Zhang, Guonan
Lou, Ge
An, Ruifang
Xia, Xiaoping
Li, Qingshui
Zhu, Yaping
Hong, Zheng
Yang, Xinfeng
Hu, Yuanjing
Zhang, Xin
Wan, Xiaoyun
Qu, Jing
Zhang, Ben
Wu, Lingying
GYNECOLOGIC ONCOLOGY, 2021, 162 : S57 - S58
[2] Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results
Ciardiello, Fortunato
Bang, Yung-Jue
Cervantes, Andres
Dvorkin, Mikhail
Lopez, Charles D.
Metges, Jean-Philippe
Sanchez Ruiz, Antonio
Calvo, Mariona
Strickland, Andrew H.
Kannourakis, George
Muro, Kei
Kawakami, Hisato
Wei, Jia
Borg, Christophe
Zhu, Zhaoyin
Gupta, Neal
Pelham, Robert J.
Shen, Lin
CANCER MEDICINE, 2023, 12 (12): : 13145 - 13154
[3] Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy
Mayerhofer, K
Kucera, E
Zeisler, H
Speiser, P
Reinthaller, A
Sevelda, P
GYNECOLOGIC ONCOLOGY, 1997, 64 (01) : 109 - 113
[4] OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab
Hardesty, Melissa M.
Krivak, Thomas C.
Wright, Gail S.
Hamilton, Erika
Fleming, Evelyn L.
Belotte, Jimmy
Keeton, Erika K.
Wang, Ping
Gupta, Divya
Clements, Aine
Gray, Heidi J.
Konecny, Gottfried E.
Moore, Richard G.
Richardson, Debra L.
GYNECOLOGIC ONCOLOGY, 2022, 166 (02) : 219 - 229
[5] A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy
Ciardiello, F.
Bang, Y-J.
Bendell, J.
Cervantes, A.
Brachmann, R.
Zhang, K.
Raponi, M.
Farin, H.
Shen, L.
ANNALS OF ONCOLOGY, 2018, 29 : 265 - 265
[6] A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD plus advanced ovarian cancer after response to front-line platinum-based chemotherapy
Gonzalez, A.
Moore, K. N.
Mirza, M. R.
Vergote, I. B.
Pothuri, B.
Oza, A. M.
Graybill, W. A.
Yalcin, I.
Agarwal, S.
Monk, B. J.
GYNECOLOGIC ONCOLOGY, 2017, 145 : 98 - 98
[7] Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial
Gordon, A.
Fong, C. Y. K.
Davidson, M.
Cromarty, S.
Kidd, S.
Piadel, K.
Peckitt, C.
Satchwell, L.
Rajan, Z.
Begum, R.
Zhitkov, O.
Das, P.
Sothi, S.
Herbertson, R. A.
Darby, S.
Waddell, T. S.
Bradshaw, A.
Starling, N.
Chau, I.
Cunningham, D.
ANNALS OF ONCOLOGY, 2023, 34 : S853 - S854
[8] Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
Wu, Xiaohua
Liu, Jihong
Wang, Jing
Wang, Li
Lin, Zhongqiu
Wang, Xiaobin
Zhu, Jianqing
Kong, Beihua
Fei, Junwei
Tang, Ying
Xia, Bairong
Liang, Zhiqing
Wang, Ke
Huang, Yi
Zheng, Hong
Lin, An
Jiang, Kui
Wang, Wei
Wang, Xin
Lou, Ge
Pan, Hongming
Yao, Shuzhong
Li, Guiling
Hao, Min
Cai, Yunlang
Chen, Xuejun
Yang, Zhijun
Chen, Youguo
Wen, Hongwu
Qu, Pengpeng
Xu, Cong
Hsieh, Chih-Yi
NATURE MEDICINE, 2024, : 1612 - 1621
[9] A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD plus advanced ovarian cancer after response to front-line platinum-based chemotherapy.
Gonzalez-Martin, Antonio
Backes, Floor Jennishens
Baumann, Klaus H.
Chase, Dana Meredith
Fehr, Mathias Konrad
Coleman, Robert L.
Freyer, Gilles
DiSilvestro, Paul
Lavie, Ofer
Herzog, Thomas J.
Lorusso, Domenica
Moore, Kathleen N.
Mirza, Mansoor Raza
O'Cearbhaill, Roisin Eilish
Vergote, Ignace
Pothuri, Bhavana
Balser, John
Agarwal, Shefali
Monk, Bradley J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
Cappuzzo, F.
Ciuleanu, T.
Stelmakh, L.
Cicenas, S.
Szczesna, A.
Juhasz, E.
Gonzalez, E. Esteban
Molinier, O.
Klingelschmitt, G.
Giaccone, G.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →